Relmada Therapeutics (RLMD) Change in Receivables (2023)

Relmada Therapeutics' (RLMD) quarterly Change in Receivables came in at -$512432.0 in Q1 2023.

Relmada Therapeutics (RLMD) Change in Receivables (2023) Analysis & Trends

Relmada Therapeutics (RLMD) has 1 years of Change in Receivables data on file, last reported at -$512432.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Relmada Therapeutics 205.29 Mn 205.29 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2023 -512,432.00
Mar 31, 2023 -512,432.00